For example, within NPM1-mutated AML, the FLT3-ITD mutation frequently co-occurs with mutations of DNMT3A, which on its own is associated with worse outcome in patients receiving standard induction therapy11. This evidence concerns the gene FLT3 and acute myeloid leukemia.